Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RAMIPRIL & HYDROCHLOROTHIAZIDE

All products: not a benefit

Other products in the same Health Canada class (C09B, C09BA) — coverage varies; not interchangeable

  • Cilazapril + hydrochlorothiazide (Inhibace Plus): general benefit
  • Hydrochlorothiazide + lisinopril (Zestoretic): general benefit, Not a benefit
  • Indapamide + perindopril erbumine (Coversyl Plus LD): general benefit
  • Hydrochlorothiazide + quinapril (Accuretic): general benefit, Not a benefit
  • Enalapril + hydrochlorothiazide (Vaseretic): not a benefit
  • Amlodipine + perindopril arginine (Viacoram): not a benefit

Altace HCT · DIN 02283158 · 5mg & 12.5mg · tablet

Listed, not a benefitDormant since 2026-07-31 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Altace HCT · DIN 02283158 Manufacturer: Sanofi Aventis Pharma; listing date 2007-06-06 Health Canada: Dormant since 2026-07-31 · brand ALTACE HCT · ATC C09BA05 RAMIPRIL AND DIURETICS, C09BA05 RAMIPRIL AND DIURETICS · form Tablet · route Oral · ingredients HYDROCHLOROTHIAZIDE 12.5 MG, RAMIPRIL 5 MG · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Altace HCT: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76877 · Verify on the e-Formulary ↗ (DIN 02283158)

Source record
DIN 02283158: Altace HCT Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800267; group id 351; item number 0808; lccId None; manufacturer id SAV Source form: Tab; strength: 5mg & 12.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02283158 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76877
Interchangeable products
Ran-Ramipril HCTZ · DIN 02449447 · $0.3016
Shortage status: discontinued (2024-01-08, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283158
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

LISINOPRIL & HYDROCHLOROTHIAZIDE

· 18 products · General benefit (10), Listed, not a benefit (2), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 10mg & 12.5mg, 20mg & 12.5mg, 20mg & 25mg, 20mg/25mg · Tab

PERINDOPRIL ERBUMINE & INDAPAMIDE

· 20 products · General benefit · strengths: 2mg & 0.625mg, 4mg & 1.25mg, 8mg & 2.5mg · Tab

QUINAPRIL & HYDROCHLOROTHIAZIDE

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 10mg & 12.5mg, 20mg & 12.5mg, 20mg & 25mg · Tab

ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg & 12.5mg, 10mg & 25mg · Tab

PERINDOPRIL ARGININE & AMLODIPINE BESYLATE

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3.5mg & 2.5mg, 7mg & 5mg, 14mg & 10mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS pms-RAMIPRIL-HCTZ (ramipril/hydrochlorothiazide) is indicated for the treatment of essential hypertension in patients for whom this combination therapy is appropriate. pms-RAMIPRIL-HCTZ is not indicated for initial therapy (see 4 DOSAGE AND ADMINISTRATION). Patients in whom ramipril and diuretic are initiated simultaneously can develop symptomatic hypotension. Patients should be titrated on individual drugs. If the fixed combination represents the dose and dosing frequency determined by this titration, the use of pms-RAMIPRIL-HCTZ may be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs. Pediatrics Pediatrics (< 18 years of age): The safety and effectiveness of ramipril and hydrochlorothiazide in pediatric patients have not been established. Therefore, pms-RAMIPRIL-HCTZ is not indicated in this patient population. Geriatrics Geriatrics (> 65 years of age): There is limited clinical experience with ramipril and hydrochlorothiazide in the elderly (> 65 years) (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00071439.PDF PM date: June 20, 2023 Source product: PMS-RAMIPRIL-HCTZ; DIN 02342154; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Altace HCT · DIN 02283158 Shortage status: discontinued (2024-01-08, reported by BAUSCH HEALTH, CANADA INC.); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02283158

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Altace HCT: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026